These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11738488)

  • 21. 2-(3-Pyridyl)thiazolidine-4-carboxamide derivatives. II. Structure-activity relationships and active configuration of 2-(3-pyridyl)thiazolidine-4-carboxamides as platelet-activating factor receptor antagonists.
    Suzuki T; Nagaoka H; Kondo Y; Takahashi T; Takeuchi M; Hara H; Saito M; Yamada T; Tomioka K; Hamada M; Mase T
    Chem Pharm Bull (Tokyo); 1998 Sep; 46(9):1468-73. PubMed ID: 9775441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.
    Cheng M; De B; Pikul S; Almstead NG; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Dowty ME; Mieling GE; Janusz MJ; Wang-Weigand S
    J Med Chem; 2000 Feb; 43(3):369-80. PubMed ID: 10669564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF).
    Nagaoka H; Hara H; Suzuki T; Takahashi T; Takeuchi M; Matsuhisa A; Saito M; Yamada T; Tomioka K; Mase T
    Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1659-64. PubMed ID: 9353894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
    Boukli L; Touaibia M; Meddad-Belhabich N; Djimdé A; Park CH; Kim JJ; Yoon JH; Lamouri A; Heymans F
    Bioorg Med Chem; 2008 Feb; 16(3):1242-53. PubMed ID: 17993277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors.
    Rew Y; DeGraffenreid M; He X; Jaen JC; McMinn DL; Sun D; Tu H; Ursu S; Powers JP
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3786-90. PubMed ID: 22542009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship studies of 1-substituted 3-dodecanoylindole-2-carboxylic acids as inhibitors of cytosolic phospholipase A2-mediated arachidonic acid release in intact platelets.
    Griessbach K; Klimt M; Schulze Elfringhoff A; Lehr M
    Arch Pharm (Weinheim); 2002; 335(11-12):547-55. PubMed ID: 12596219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s.
    Assogba L; Ahamada-Himidi A; Habich NM; Aoun D; Boukli L; Massicot F; Mounier CM; Huet J; Lamouri A; Ombetta JE; Godfroid JJ; Dong CZ; Heymans F
    Eur J Med Chem; 2005 Sep; 40(9):850-61. PubMed ID: 16084626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-(Arylpiperazinylamidoalkyl)-pyrimidones: orally active inhibitors of lipoprotein-associated phospholipase A(2).
    Bloomer JC; Boyd HF; Hickey DM; Ife RJ; Leach CA; Macphee CH; Milliner KJ; Pinto IL; Rawlings DA; Smith SA; Stansfield IG; Stanway SJ; Taylor MA; Theobald CJ; Whittaker CM
    Bioorg Med Chem Lett; 2001 Jul; 11(14):1925-9. PubMed ID: 11459662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that 85 kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes.
    Winkler JD; Bolognese BJ; Roshak AK; Sung CM; Marshall LA
    Biochim Biophys Acta; 1997 Jun; 1346(2):173-84. PubMed ID: 9219900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.
    Piwinski JJ; Wong JK; Green MJ; Kaminski JJ; Colizzo F; Albanese MM; Ganguly AK; Billah MM; Anthes JC; West RE
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3469-74. PubMed ID: 9934454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
    Trova MP; Wissner A; Carroll ML; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Kohler CA
    J Med Chem; 1993 Mar; 36(5):580-90. PubMed ID: 8496938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2).
    Lehr M; Klimt M; Elfringhoff AS
    Bioorg Med Chem Lett; 2001 Oct; 11(19):2569-72. PubMed ID: 11551751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
    Baroggi N; Etienne A; Braquet P
    Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.
    Kohler C; Carroll M; Tarrant E; Torley L; Wissner A
    Inflammation; 1993 Jun; 17(3):245-61. PubMed ID: 8330926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets.
    Benveniste J; Chignard M; Le Couedic JP; Vargaftig BB
    Thromb Res; 1982 Mar; 25(5):375-85. PubMed ID: 6803388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
    Chonan T; Oi T; Yamamoto D; Yashiro M; Wakasugi D; Tanaka H; Ohoka-Sugita A; Io F; Koretsune H; Hiratate A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6645-8. PubMed ID: 19853443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives.
    Meddad-Belhabich N; Aoun D; Djimdé A; Redeuilh C; Dive G; Massicot F; Chau F; Heymans F; Lamouri A
    Bioorg Med Chem; 2010 May; 18(10):3588-600. PubMed ID: 20417107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity.
    Le Texier L; Favre E; Redeuilh C; Blavet N; Bellahsene T; Dive G; Pirotzky E; Godfroid JJ
    J Lipid Mediat Cell Signal; 1996 May; 13(3):189-205. PubMed ID: 8816984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme.
    Dong CZ; Ahamada-Himidi A; Plocki S; Aoun D; Touaibia M; Meddad-Bel Habich N; Huet J; Redeuilh C; Ombetta JE; Godfroid JJ; Massicot F; Heymans F
    Bioorg Med Chem; 2005 Mar; 13(6):1989-2007. PubMed ID: 15727853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
    Weber KH; Heuer H
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.